Stocks and Investing
by (remove) : Matthew Kaplan
RSSJSONXMLCSV
Stocks and Investing
by (remove) : Matthew Kaplan
RSSJSONXMLCSV
Fri, June 14, 2024
Thu, May 2, 2024
Thu, April 18, 2024
Thu, August 3, 2023
Thu, May 4, 2023
Tue, May 2, 2023
Wed, June 29, 2022
Fri, February 25, 2022
Wed, December 1, 2021
Thu, October 14, 2021
Wed, January 22, 2020
Thu, August 1, 2019
Fri, October 28, 2016
Fri, April 29, 2016
Thu, March 31, 2016
Mon, December 23, 2013
Mon, April 30, 2012

Matthew Kaplan Maintained (URGN) at Strong Buy with Increased Target to $54 on, Jun 14th, 2024


Published on 2024-10-28 11:57:20 - WOPRAI, Matthew Kaplan
  Print publication without navigation


Matthew Kaplan of Ladenburg Thalmann, Maintained "UroGen Pharma Ltd." (URGN) at Strong Buy with Increased Target from $48 to $54 on, Jun 14th, 2024.

Matthew, nor any peers, have made any analyst calls on URGN in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources